Biolegend, 796504, Biotinylated Recombinant Human HER2-Fc Chimera (carrier-free)

[{"group": "General", "name": "Source", "value": "Human HER2, amino acid (Gln24-Leu651) (Accession: NM_004448.2), with a C-terminal human IgG1 (Pro100-Lys330), and an Avi-tag, was expressed in CHO cells. Human HER2-Avi tag was site-specifically biotinylated by enzyme BirA."}, {"group": "General", "name": "Molecular Mass", "value": "The 891 amino acid recombinant protein has a predicted molecular mass of approximately 98.3 kD. The protein migrates at approximately 120 kD and 240 kD by SDS-PAGE in DTT-reduced and non-reduced conditions, respectively. The predicted N-terminal amino acid is Gln."}, {"group": "General", "name": "Purity", "value": "> 95%, as determined by Coomassie stained SDS-PAGE"}, {"group": "General", "name": "Formulation", "value": "0.22 µm filtered protein solution is in PBS pH 7.2."}, {"group": "General", "name": "Endotoxin Level", "value": "Less than 0.1 EU per µg cytokine as determined by the LAL method"}, {"group": "General", "name": "Concentration", "value": "25 µg size is bottled at 200 µg/mL. 100 µg size and larger sizes are lot-specific and bottled at the concentration indicated on the vial. To obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool."}, {"group": "General", "name": "Storage & Handling", "value": "Unopened vial can be stored between 2°C and 8°C for up to 2 weeks at -20°C for up to six months, or at -70°C or colder until the expiration date. For maximum results, quick spin vial prior to opening. The protein can be aliquoted and stored at -20°C or colder. Stock solutions can also be prepared at 50 - 100 µg/mL in appropriate sterile buffer, carrier protein such as 0.2 - 1% BSA or HSA can be added when preparing the stock solution. Aliquots can be stored between 2°C and 8°C for up to one week and stored at -20°C or colder for up to 3 months. Avoid repeated freeze/thaw cycles."}, {"group": "General", "name": "Activity", "value": "Human HER2 is measured by its ability to block anti-human ErbB2/HER2 (clone 4D5-8, trastuzumab) antibody inhibition of SK-BR-3 cell proliferation. The ED50 for this effect is 0.1 – 0.6 µg/mL."}, {"group": "General", "name": "Application", "value": "Bioassay"}, {"group": "General", "name": "Application Notes", "value": "BioLegend carrier-free recombinant proteins provided in liquid format are shipped on blue-ice. Our comparison testing data indicates that when handled and stored as recommended, the liquid format has equal or better stability and shelf-life compared to commercially available lyophilized proteins after reconstitution. Our liquid proteins are validated in-house to maintain activity after shipping on blue ice and are backed by our 100% satisfaction guarantee. If you have any concerns, contact us at [email protected]."}, {"group": "General", "name": "Product Citations", "value": "Cheng K, et al. 2023. Int J Mol Sci. 24:. PubMed"}, {"group": "General", "name": "Structure", "value": "Dimer"}, {"group": "General", "name": "Distribution", "value": "Many tissues, overexpressed in breast cancers and gastric cancer"}, {"group": "General", "name": "Function", "value": "Cell development, proliferation, survival, and motility"}, {"group": "General", "name": "Interaction", "value": "HER2 (ErbB2) forms dimers with EGFR, ErbB2, ErbB3, and ErbB4"}, {"group": "General", "name": "Ligand/Receptor", "value": "No ligand is known for ErbB2"}, {"group": "General", "name": "Bioactivity", "value": "Human HER2 blocks the activity of anti-human ErbB2/HER2 (clone 4D5-8, trastuzumab) antibody inhibition of SK-BR-3 cell proliferation."}, {"group": "General", "name": "Cell Type", "value": "Epithelial cells"}, {"group": "General", "name": "Biology Area", "value": "Cancer Biomarkers, Cell Biology, Immuno-Oncology, Immunology"}, {"group": "General", "name": "Molecular Family", "value": "CD Molecules, Soluble Receptors"}, {"group": "General", "name": "Antigen References", "value": "Olayioye MA. 2001. Breast Cancer Res. 3:385. Cho HS, et al. 2003. Nature. 421: 756 Garret TP, et al. 2003. Mol. Cell. 11: 495. Bublil EM, Yarden Y. 2007. COCEBI. 19:124. MA Lemmon. 2009. Exp. Cell. Res. 315:638. Mitri Z, et al. 2012. Chemother. Res. Pract. 2012:743193. Sawyer CL. 2019. Cell. 179: 8. Maddi H, et al. 2021. Cancer (Basel). 13:3540. Meric-Bernstam F, et al. 2019. Clin. Cancer Res. 25:2033."}, {"group": "General", "name": "Gene ID", "value": "2064"}, {"group": "General", "name": "UniProt", "value": "View information about HER2 on UniProt.org"}, {"group": "General", "name": "Regulatory Status", "value": "RUO"}, {"group": "General", "name": "Other Names", "value": "ErbB2, Neu, CD340, TKR1, Herstatin, Proto-Oncogene Neu, human epidermal growth factor receptor 2, Receptor Tyrosine-Protein Kinase ErbB-2."}]